Effect of a 300 mg single-dose autoinjector of secukinumab in people with moderate to severe plaque psoriasis

Full results from the phase 3 trial show that the single-dose autoinjector in conjunction with patient support materials is safe and effective for people with moderate to severe plaque psoriasis. For more results from MATURE, a randomized, placebo-controlled trial, visit www.mature-psoriasis.org.

Date: September 2021

Please note that the summary only contains results from the full EADV 2021 study and is intended for educational use and reference. The results of this study are not founded on or criticized by other studies.

This summary is not intended for commercial or promotional use.

What was the MATURE study conducted to?
To evaluate the efficacy, safety, and tolerability of 12 months of secukinumab, delivered in a single-dose autoinjector, compared with 2x 150 mg injections every 4 weeks, in adults with moderate to severe plaque psoriasis.

Patient satisfaction scores continued up to Week 52 (1 year) in both secukinumab groups. Higher quality of life scores were reported in those in both groups treated with secukinumab (71.1% with the Quality of Life measure and 73.2% with the Patient Global Assessment measure). The proportion of “satisfied” or “very satisfied” patients increased from 31.6% before treatment to 78.3% at Week 12 (secukinumab groups) compared with 53.3% and 59.7% in the placebo group. Patient satisfaction scores remained stable from Week 12 to Week 52.

What did this study look at?
The severity of psoriasis in the patient sample was assessed using scoring systems, such as Psoriasis Area and Severity Index (PASI), which allow the effectiveness of therapies used in psoriasis patients to be compared with the severity of the disease. Monitoring quality of life (QoL) is a key metric to evaluate symptoms and adverse events in addition to efficacy, as the real-world benefits of any treatment are best evaluated with a balanced approach.

To our knowledge, this is the first randomized controlled trial (RCT) to evaluate a single-dose secukinumab autoinjector administered via autoinjector at 300 mg in adult patients with moderate to severe plaque psoriasis.

What did the MATURE study find?

Efficacy

The mean PASI 75 at Week 12 was 62.6% (SD 15.7) for the secukinumab groups and 41.0% (SD 29.5) for the placebo group. A loading dose of 4x weekly injections was administered, followed by 1x injection every 4 weeks.

Patient satisfaction

A loading dose of 4x weekly injections was administered, followed by 1x injection every 4 weeks. Satisfaction scores increased from 31.6% before treatment to 78.3% at Week 12 in the secukinumab groups.

Quality of life

Higher QoL was observed in the secukinumab groups at Week 12 compared with placebo (53.3% vs. 59.7%). Treatment-emergent adverse events were reported in 33.2% of patients in the secukinumab group and 19.0% in the placebo group. No new safety signals were observed after one year. Throughout the study, only two patients reported serious adverse events.